<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326999</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-2153</org_study_id>
    <nct_id>NCT03326999</nct_id>
  </id_info>
  <brief_title>Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?</brief_title>
  <official_title>Evaluating the Addition of Obturator Nerve Block to Adductor Canal Block for Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One common anesthetic that is performed for total knee replacement surgery is spinal&#xD;
      anesthesia with an adductor canal regional block, which involves injecting numbing medication&#xD;
      in the thigh region for pain control after surgery. The aim of this study is to determine&#xD;
      whether the addition of another regional block called obturator nerve block, which involves&#xD;
      injecting numbing medication in the upper thigh region, will improve pain control after&#xD;
      surgery while not sacrificing mobility after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is currently no consensus on the optimal strategy that provides the most effective&#xD;
      postoperative analgesia while preserving ambulation and limiting side effects such as nausea&#xD;
      and vomiting. The clinical team's hypothesis is that the obturator nerve block in addition to&#xD;
      adductor canal block can target both the anterior and posterior distribution of nerves to the&#xD;
      knee to provide superior analgesia while not limiting ambulation. To test this hypothesis,&#xD;
      the clinical team will compare the rate of IV opioid consumption in patients who receive a&#xD;
      combination of adductor canal block and obturator nerve block at the surgical site versus&#xD;
      patients who receive adductor canal block alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">December 18, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial with two arms: one arm will receive adductor canal block and obturator nerve block with the local anesthetic bupivacaine; second arm will receive adductor canal block with bupivacaine and obturator nerve block with saline.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine Equivalence Consumption</measure>
    <time_frame>up to 24 hours after surgery</time_frame>
    <description>Total amount of opioids consumed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>1, 6, 12, and 24 hours after surgery</time_frame>
    <description>Likert scale ranging from 0-10 - 0 being no pain, and 10 being the worst pain ever experienced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nausea or Vomiting</measure>
    <time_frame>up to 24 hours after surgery</time_frame>
    <description>Yes or No responses when the subject is asked if the subject is feeling nauseous or has vomited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>on postoperative day 1 after surgery</time_frame>
    <description>The length of time that it takes before the patient is first able to walk with assistance after surgery as assessed by a physical therapist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Breakthrough Pain Medication</measure>
    <time_frame>up to post operative day 2 after surgery</time_frame>
    <description>Time before pain medication needed for breakthrough pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia Satisfaction Score</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>Analgesia Satisfaction Score - Full scale from 0-10 with higher score indicating higher satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Knee Rheumatism</condition>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obturator nerve regional block</intervention_name>
    <description>Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.</description>
    <arm_group_label>Investigational arm</arm_group_label>
    <other_name>bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adductor canal regional block</intervention_name>
    <description>Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline as placebo comparator</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled to undergo total knee arthroplasty&#xD;
&#xD;
          -  Planned use of regional anesthesia for procedure&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on immunosuppressive therapy&#xD;
&#xD;
          -  Patients with history of diabetes&#xD;
&#xD;
          -  Patients with lower limb neuropathy&#xD;
&#xD;
          -  Patients with history of chronic opioid use for &gt; 3 months, including but not limited&#xD;
             to, fentanyl, morphine, oxycodone, methadone&#xD;
&#xD;
          -  Patients with known allergy or intolerance to any drug used in the study&#xD;
&#xD;
          -  Patients with history of alcohol or drug abuse&#xD;
&#xD;
          -  Patients with history of intolerance of nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Patients with hepatic or renal insufficiency&#xD;
&#xD;
          -  ASA score of 4 or greater&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Jeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Runge C, BÃ¸rglum J, Jensen JM, Kobborg T, Pedersen A, Sandberg J, Mikkelsen LR, Vase M, Bendtsen TF. The Analgesic Effect of Obturator Nerve Block Added to a Femoral Triangle Block After Total Knee Arthroplasty: A Randomized Controlled Trial. Reg Anesth Pain Med. 2016 Jul-Aug;41(4):445-51. doi: 10.1097/AAP.0000000000000406.</citation>
    <PMID>27171822</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Christina Jeng</investigator_full_name>
    <investigator_title>Christina Jeng MD Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>adductor canal regional block</keyword>
  <keyword>obturator nerve regional block</keyword>
  <keyword>total knee arthroplasty</keyword>
  <keyword>knee replacement surgery</keyword>
  <keyword>Knee rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03326999/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03326999/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in October with enrollment from December 2017 through December 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Investigational Arm</title>
          <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine Arm</title>
          <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
        </group>
        <group group_id="B2">
          <title>Saline Control Arm</title>
          <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="7.5"/>
                    <measurement group_id="B2" value="66.7" spread="7.3"/>
                    <measurement group_id="B3" value="67.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.72" spread="4.85"/>
                    <measurement group_id="B2" value="28.65" spread="5.05"/>
                    <measurement group_id="B3" value="29.68" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morphine Equivalence Consumption</title>
        <description>Total amount of opioids consumed</description>
        <time_frame>up to 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Saline Control Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Equivalence Consumption</title>
          <description>Total amount of opioids consumed</description>
          <units>MME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="6.37"/>
                    <measurement group_id="O2" value="18.85" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score</title>
        <description>Likert scale ranging from 0-10 - 0 being no pain, and 10 being the worst pain ever experienced</description>
        <time_frame>1, 6, 12, and 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Saline Control Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score</title>
          <description>Likert scale ranging from 0-10 - 0 being no pain, and 10 being the worst pain ever experienced</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.64"/>
                    <measurement group_id="O2" value="0.23" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="2.82"/>
                    <measurement group_id="O2" value="2.77" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="2.92"/>
                    <measurement group_id="O2" value="5.13" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" spread="2.66"/>
                    <measurement group_id="O2" value="7.00" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nausea or Vomiting</title>
        <description>Yes or No responses when the subject is asked if the subject is feeling nauseous or has vomited</description>
        <time_frame>up to 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Saline Control Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nausea or Vomiting</title>
          <description>Yes or No responses when the subject is asked if the subject is feeling nauseous or has vomited</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulation</title>
        <description>The length of time that it takes before the patient is first able to walk with assistance after surgery as assessed by a physical therapist.</description>
        <time_frame>on postoperative day 1 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Saline Control Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation</title>
          <description>The length of time that it takes before the patient is first able to walk with assistance after surgery as assessed by a physical therapist.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.98" spread="8.13"/>
                    <measurement group_id="O2" value="7.87" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Breakthrough Pain Medication</title>
        <description>Time before pain medication needed for breakthrough pain</description>
        <time_frame>up to post operative day 2 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Saline Control Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Breakthrough Pain Medication</title>
          <description>Time before pain medication needed for breakthrough pain</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872.54" spread="1044.07"/>
                    <measurement group_id="O2" value="510.13" spread="420.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesia Satisfaction Score</title>
        <description>Analgesia Satisfaction Score - Full scale from 0-10 with higher score indicating higher satisfaction.</description>
        <time_frame>2 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Saline Control Arm</title>
            <description>Patients in this arm received adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesia Satisfaction Score</title>
          <description>Analgesia Satisfaction Score - Full scale from 0-10 with higher score indicating higher satisfaction.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.24" spread="0.93"/>
                    <measurement group_id="O2" value="8.59" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks post surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Investigational Arm</title>
          <description>Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christina Jeng</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6426</phone>
      <email>christina.jeng@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

